Liquid biopsy molecular profiling of hepatocellular carcinoma after Y-90 radioembolization
Official title: Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization and Assessment of Treatment Response After Y90 Radioembolization: A Pilot Study
Run by Palo Alto Veterans Institute for Research · NCT07303712 · Data updated 2026-11-12
This will test whether blood liquid biopsies (circulating tumor cells and cell-free DNA) taken before and after Y-90 radioembolization can help predict which adults with hepatocellular carcinoma will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Palo Alto Veterans Institute for Research Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | August 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT07303712 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with imaging-confirmed hepatocellular carcinoma (BCLC stage 0–C) who are approved for transarterial Y-90 radioembolization and can complete scheduled follow-up visits.
✕Probably not a fit
Patients not eligible for Y-90, those with prior surgery or ablation of the target tumors, individuals unable to attend required follow-up, or patients whose tumors do not shed detectable circulating markers are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect baseline and serial blood samples to measure circulating tumor cells (CTCs), single-cell CTC DNA, and cell-free DNA before and over 6–9 months after Y-90 radioembolization. Tumor-derived mutations and temporal changes in CTC/cfDNA will be compared with imaging-based response outcomes at 6–9 months and with radiomic features. Predictive models using liquid biopsy data alone, imaging data alone, and combined multiomic approaches will be developed to identify markers associated with treatment response. The study enrolls adults with BCLC stage 0 through C HCC who are approved for Y-90 by a multidisciplinary tumor board.
Why it matters
Potential benefit: If successful, this approach could enable earlier, blood-based prediction of who will benefit from Y-90 and help personalize follow-up and additional therapies.
How similar studies have gone: Prior work has shown that cfDNA and CTC assays can detect HCC mutations and reflect disease burden, but using single-cell CTC DNA dynamics specifically to predict Y-90 response is relatively novel and unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> or = 18 years 2. HCC confirmed on imaging, BCLC stage 0, A, B, or C 3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board - Exclusion Criteria: 1. Not eligible for Y90 procedure 2. Prior surgery or ablation on indicated tumors 3. Patient unable to complete the follow up visits required for clinical care or research -
Where it's running
-
VA Palo Alto Health Care System
Palo Alto, California, United States Recruiting
Study contacts
- Principal investigator: Sirish Kishore, MD — VA Palo Alto Health Care System
- Study coordinator: Sirish Kishore, MD
- Email: sirish.kishore@va.gov
- Phone: 650-493-5000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC
This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.